Artificial pancreas with two hormones could ease diabetes management
NCT ID NCT05669547
First seen Jan 22, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study tested a fully automated system that delivers both insulin and glucagon to manage blood sugar in adults with type 1 diabetes. Over 12 months, 243 participants used either the dual-hormone device or their usual care. The goal was to see if the system helps keep blood sugar in a healthy range more consistently.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amsterdam UMC, AMC
Amsterdam, Netherlands
-
Amsterdam UMC, VUmc
Amsterdam, Netherlands
-
Catharina Ziekenhuis
Eindhoven, Netherlands
-
Gelre Ziekenhuis
Apeldoorn, Netherlands
-
Isala Klinieken
Zwolle, Netherlands
-
LUMC
Leiden, Netherlands
-
Martini Ziekenhuis
Groningen, Netherlands
-
Meander MC
Amersfoort, Netherlands
-
OLVG
Amsterdam, Netherlands
-
Rijnstate
Arnhem, Netherlands
-
St. Antonius
Nieuwegein, Netherlands
-
Tergooi Ziekenhuis
Hilversum, Netherlands
-
UMC Groningen
Groningen, Netherlands
-
UMC Utrecht
Utrecht, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dual-hormone fully closed loop system (Inreda AP device delivering insulin and glucagon)
What this could lead to
If successful, this could offer a more automated way to manage type 1 diabetes, reducing the daily burden of constant monitoring and manual insulin dosing.
What could go wrong
This is a completed trial, but results are not yet widely known. The system is complex and may have technical issues or side effects like low blood sugar. It is not a cure and requires ongoing use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.